Overview Dividends

(VKTX) Viking Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92686J1060

VK2809, VK2735, VK5211, VK0214, VK0612

EPS (Earnings per Share)

EPS Growth (3y CAGR): -67.80%
EPS Trend (3y Corr): -74.2%

Last SUE: -2.00σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): 0.00%
Revenue Trend (3y Corr): -13.1%

Last SUE: 0.00σ
Qual. Beats: 0

Risk via 10d forecast
Volatility	84.3%
Value at Risk 5%th	115%
Relative Tail Risk	-16.87%

Reward TTM
Sharpe Ratio	-0.09
Alpha	-47.48

Character TTM
Hurst Exponent	0.512
Beta	1.613
Beta Downside	1.380

Drawdowns 3y
Max DD	78.86%
Mean DD	39.27%
Median DD	40.87%

Description: VKTX Viking Therapeutics November 08, 2025

Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharma focused on metabolic and endocrine disorders. Founded in 2012 and based in San Diego, the company’s pipeline centers on orally bioavailable, tissue-selective hormone receptor modulators.

The lead asset, VK2809, is a thyroid-hormone-receptor-beta (TRβ) agonist currently in a Phase IIb trial for biopsy-confirmed non-alcoholic steatohepatitis (NASH) and broader NAFLD. Independent market forecasts estimate the global NASH therapeutic market could exceed $30 billion by 2028, making successful validation of VK2809 a potentially high-impact catalyst.

Beyond VK2809, Viking is advancing four additional candidates: VK5211 (a selective androgen receptor modulator in Phase II for post-hip-fracture recovery), VK0612 (a TRβ agonist positioned for Phase IIb in type-2 diabetes), VK2735 (a dual GLP-1/glucagon agonist in Phase I SAD/MAD), and VK0214 (a TRβ agonist for X-linked adrenoleukodystrophy). All are oral small molecules, which aligns with the sector’s preference for scalable, low-cost manufacturing.

As of the latest quarterly filing (Q2 2024), Viking reported cash and equivalents of roughly $150 million and a quarterly cash burn of $30 million, implying a runway into 2026 assuming no material financing events. The company’s R&D intensity (~45 % of total expenses) is typical for early-stage biotech, but also underscores the importance of timely trial readouts to preserve liquidity.

If you’re looking for a data-driven deep-dive on Viking’s valuation assumptions and scenario analysis, ValueRay’s platform offers a transparent framework worth exploring.

VKTX Stock Overview

Market Cap in USD	4,268m
Sub-Industry	Biotechnology
IPO / Inception	2015-04-29
Return 12m vs S&P 500	-40.5%
Analyst Rating	4.42 of 5

VKTX Dividends

Currently no dividends paid

VKTX Growth Ratios

Metric	Value
CAGR 3y	105.82%
CAGR/Max DD Calmar Ratio	1.34
CAGR/Mean DD Pain Ratio	2.69
Current Volume	3746.9k
Average Volume	3921.6k

Piotroski VR‑10 (Strict, 0-10) 0.0

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)

FCFTA -0.30 (>2.0%) and ΔFCFTA -22.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)

CFO/TA -0.30 (>3.0%) and CFO -224.6m > Net Income -237.4m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 28.34 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (112.3m) change vs 12m ago 1.27% (target <= -2.0% for YES)

error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)

Asset Turnover 0.0% (prev 0.05%; Δ -0.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -5150 (EBITDA TTM -246.8m / Interest Expense TTM 48.0k) >= 6 (WARN >= 3)

Altman Z'' -26.14

(A) 0.96 = (Total Current Assets 738.7m - Total Current Liabilities 26.1m) / Total Assets 739.4m

(B) -0.93 = Retained Earnings (Balance) -689.9m / Total Assets 739.4m

(D) -26.13 = Book Value of Equity -689.5m / Total Liabilities 26.4m

Total Rating: -26.14 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 39.52

1. Piotroski 0.0pt

2. FCF Yield -6.32%

3. FCF Margin data missing

4. Debt/Equity 0.00

5. Debt/Ebitda 0.40

7. RoE -29.35%

8. Rev. Trend -13.10%

9. EPS Trend -74.20%

What is the price of VKTX shares?

As of November 21, 2025, the stock is trading at USD 34.27 with a total of 3,746,854 shares traded.
Over the past week, the price has changed by -12.13%, over one month by +1.54%, over three months by +33.40% and over the past year by -33.50%.

Is VKTX a buy, sell or hold?

Viking Therapeutics has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy VKTX.

Strong Buy: 10
Buy: 7
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the VKTX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	93.4	172.5%
Analysts Target Price	93.4	172.5%
ValueRay Target Price	44.4	29.6%

VKTX Fundamental Data Overview November 20, 2025

Market Cap USD = 4.27b (4.27b USD * 1.0 USD.USD)
P/B = 5.9861
P/EG = -0.03
Beta = 0.633
Revenue TTM = 0.0 USD
EBIT TTM = -247.2m USD
EBITDA TTM = -246.8m USD
Long Term Debt = 755.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 437.0k USD (from shortTermDebt, last quarter)
Debt = 755.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -99.6m USD (from netDebt column, last quarter)
Enterprise Value = 3.55b USD (4.27b + Debt 755.0k - CCE 714.6m)
Interest Coverage Ratio = -5150 (Ebit TTM -247.2m / Interest Expense TTM 48.0k)
FCF Yield = -6.32% (FCF TTM -224.6m / Enterprise Value 3.55b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 336.0k) / Revenue TTM)
Tobins Q-Ratio = 4.81 (Enterprise Value 3.55b / Total Assets 739.4m)
Interest Expense / Debt = 3.18% (Interest Expense 24.0k / Debt 755.0k)
Taxrate = 100.0% (out of range, set to none) (-110.0m / -110.0m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 28.34 (Total Current Assets 738.7m / Total Current Liabilities 26.1m)
Debt / Equity = 0.00 (Debt 755.0k / totalStockholderEquity, last quarter 713.0m)
Debt / EBITDA = 0.40 (negative EBITDA) (Net Debt -99.6m / EBITDA -246.8m)
Debt / FCF = 0.44 (negative FCF - burning cash) (Net Debt -99.6m / FCF TTM -224.6m)
Total Stockholder Equity = 808.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.11% (Net Income -237.4m / Total Assets 739.4m)
RoE = -29.35% (Net Income TTM -237.4m / Total Stockholder Equity 808.9m)
RoCE = -30.53% (EBIT -247.2m / Capital Employed (Equity 808.9m + L.T.Debt 755.0k))
RoIC = 20.2k% (out of range, set to none) (EBIT -247.2m / (Assets 739.4m - Curr.Liab 26.1m - Cash 714.6m))
WACC = 11.96% (E(4.27b)/V(4.27b) * Re(11.96%) + (debt cost/tax rate unavailable))
Discount Rate = 11.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.92%
Fair Price DCF = unknown (Cash Flow -224.6m)
EPS Correlation: -74.20 | EPS CAGR: -67.80% | SUE: -2.00 | # QB: 0
Revenue Correlation: -13.10 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for VKTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle